Clinical trial · Interventional
Osteoconduction Potential of an Injectable Calcium Phosphate in Orthopaedic Surgery in Fillings of Osseous Defects
Study of Osteoconduction Potential of an Injectable Calcium Phosphate in Orthopaedic Surgery in Fillings of Osseous Defects From Various Origins
NCT00206791CI-TRIAL-00085551completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this non-comparative study is to test, for the first time, the bioactivity of a new "ready to use" calcium phosphate biomaterial in fillings of little losses of osseous substance from various origins, such as traumatic and benign tumoral causes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Grafting, Bone | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MBCP Gel | Device | — | UNRESOLVED |
| MBCP-Gel (tm) | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- MBCPGel
- interventionNames
- Device: MBCP-Gel (tm)
- Device: MBCP Gel
Primary outcomes (1)
- measure
- Presence or absence of an edging to radiolucent on the radiographic stereotypes between the biomaterial and the osseous walls of the osseous defect at different times (3, 6 and 12 months after surgery)
- timeFrame
- 3, 6 and 12 months
Secondary outcomes (1)
- measure
- An analysis of numeric radiographic stereotypes by grey steps will study the evolution of the density of the implant and environmental bone.
- timeFrame
- 3, 6 and 12 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Medium osseous defects (inferior to 20 cc) without articular communication * Patients without a personal medical history of bone infection, cancer, diabetes, tuberculosis, and in general, any pathology which could interfere with the results of the study or expose the patient to additional risk * Patients without drepanocytosis, or congenital or acquired immunizing deficit * Patients who have the benefit of a social security system, a previous medical exam and who were informed and gave free consent about this study Exclusion Criteria: * Proven nicotinism and alcoholism * Pregnant or nursing women * Patients who received another study drug or another study device in the past 3 months or patients who will be included in another clinical study * If postoperative follow-up for a patient is considered to be random by the investigator, he/she should not be included
References
Publications (0)
Data not yet available
No reference posted for this study.